An update from Passage Bio ( (PASG) ) is now available.
Passage Bio Inc. presented promising interim data from their upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias, showcasing the effective treatment of frontotemporal dementia with their gene therapy, PBFT02. The treatment was well-tolerated, with patients showing sustained elevated levels of progranulin in their cerebral spinal fluid for up to a year post-treatment, indicating potential as a significant therapy for neurodegenerative diseases. This data supports the company’s strategy to advance this treatment for additional conditions, highlighting their commitment to improving the lives of patients with neurodegenerative diseases.
See more insights into PASG stock on TipRanks’ Stock Analysis page.
